^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UV1

    i
    Associations
    News

    Trials

    Company:
    Zelluna
    Drug class:
    Immunostimulant, hTERT inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU) (NCT04300244)
    Phase 2
    Åslaug Helland
    Active, not recruiting
    Last update posted :
    02/29/2024
    Initiation :
    05/04/2020
    Primary completion :
    03/15/2025
    Completion :
    03/15/2027
    TMB
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Leukine (sargramostim) • UV1
    UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma (UV1-103) (NCT03538314)
    Phase 1
    Ultimovacs ASA
    Active, not recruiting
    Last update posted :
    11/17/2022
    Initiation :
    07/09/2018
    Primary completion :
    10/01/2022
    Completion :
    10/01/2025
    BRAF
    |
    Keytruda (pembrolizumab) • UV1
    Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS) (NCT05075122)
    Phase 2
    Martin-Luther-Universität Halle-Wittenberg
    Recruiting
    Last update posted :
    03/09/2022
    Initiation :
    08/02/2021
    Primary completion :
    08/01/2024
    Completion :
    02/01/2025
    PD-L1 • IFNG
    |
    Keytruda (pembrolizumab) • Leukine (sargramostim) • UV1